The Prescription Drug Affordability Board posted the agenda for its next meeting on February 21. Ozempic, Trulicity and Shingrix are listed on the agenda for affordability review. Please register in advance of the meeting.
Also in Oregon, the Board of Pharmacy posted the agenda and meeting materials for its special board meeting on February 23.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy posted the agenda and meeting materials for its February 7-9 meeting. Please note the board will meet in Executive Session immediately after roll call for most of the day on February 7 and February 8 and anticipates resuming “Open Session” between 4:30 pm and 5:00 pm on both days.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Prescription Drug Affordability Board meeting has been rescheduled to January 26. The registration link and meeting agenda have been posted online.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Prescription Drug Affordability Board posted a draft agenda for the January 17 meeting. Board calendar and materials from past meetings are also available online.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy announced the December 13-15 Board meeting agenda and meeting materials are now available. Please note the consideration of rules for adoption related to vaccines pursuant to the enactment of HB 2486 and HB 2278 this year.
Also in Oregon, the Prescription Drug Affordability Board posted a draft agenda for the December 13 meeting. Board calendar and materials from past meetings are also available online.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy posted the November 2023 Newsletter including the following headlines:
Also in Oregon, the Oregon Health Authority announced the Immunization Policy Advisory Team (IPAT) will meet on December 7 and posted an agenda for this meeting.
Finally in Oregon, the Department of Consumer and Business Services will be hosting a public hearing on prescription drug prices on December 7 from 1:30 pm to 4:00 pm via Zoom.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Prescription Drug Affordability Board (PDAB) posted its November 15 meeting draft agenda. The PDAB will also review an updated working drug list during the November 15 meeting; the updated list has been posted on the PDAB data page. Below are links to information for the next meeting including current rules referenced in the draft agenda. The board calendar and minutes from past meetings are also available online.
Also in Oregon, the Oregon Health Authority proposed minor housekeeping edits to align with Federal requirements, clarify language, remove outdated references, and correct typos. Comments are due November 21 at 5:00 pm Pacific.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy issued a public notice of and agenda for its Strategic Planning Meeting scheduled to be held November 8-9, 2023. See agenda for details to participate in the meeting either in-person or virtually.
Also in Oregon, On August 11, 2023, the Oregon Board of Pharmacy voted to permanently adopt, effective March 1, 2024, OAR 855-115-0150(3) Pharmacist: Prohibited Practices. This rule says that pharmacists are not allowed to diagnose patients. The Board adopted this rule because there is no authority in ORS chapter 689 for pharmacists to diagnose and the Board wanted to make sure that pharmacists know this. On September 25, 2023, the Oregon Board of Pharmacy received a petition to repeal OAR 855-115-0150(3) pursuant to OAR 137-001-0070 Petition to Promulgate, Amend, or Repeal Rule; see below for details.
Proposed Amendments: OAR 855-115-0150(3) Pharmacist: Prohibited Practices
Petitioner's proposed amendment:
"Pharmacists must not:"
"(3) Diagnose."
Pursuant to OAR 137-001-0070(3), the Board of Pharmacy is inviting written public comment on the adopted rule, including
(a) Options for achieving the existing rule's substantive goals while reducing the negative economic impact on businesses;
(b) The continued need for the existing rule;
(c) The complexity of the existing rule;
(d) The extent to which the existing rule overlaps, duplicates, or conflicts with other state or federal rules and with local government regulations;
(e) The degree to which technology, economic conditions, or other factors have changed in the subject area affected by the existing rule, since the agency adopted the rule; and
Written public comments may be submitted to the Board of Pharmacy by email at pharmacy.rulemaking@bop.oregon.gov. The public comment period will close on November 15 at 4:30 pm. The board will review the public comments received at the December board meeting and will in writing, within 90 days after receipt of the petition, either deny the petition or initiate rulemaking proceedings pursuant to OAR 137-001-0070(4)(c). If you have any questions, please reach out to the Rules Coordinator, at pharmacy.rulemaking@bop.oregon.gov.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy permanently adopted the following rules at the October 2023 Board Meeting effective October 17, 2023, unless otherwise noted:
Also in Oregon, the Board of Pharmacy announced the agency's new director, Jamal Fox. Fox has more than 20 years of experience in the public and private sectors. Fox will start his new role with the agency beginning October 25.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
